AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Chemomab Therapeutics Ltd.
Video analysis: CMMB
All videosNo video analysis for this stock yet. Request one from our team.
News: CMMB
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C.
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Planned merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in RA continues to advance with closing expected by year-end
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Chemomab and Scipher announced a merger agreement to advance nebokitug into a Phase 2 precision medicine trial for the treatment of rheumatoid arthritis.
Similar companies
-
Kazia Therapeutics Ltd ADR
KZIA
·
NASDAQ
Compare
-
Ocean Biomedical, Inc.
OCEA
·
Other OTC
Compare
-
Theriva Biologics, Inc.
TOVX
·
New York Stock Exchange Arca
Compare
-
PMGC Holdings Inc.
ELAB
·
NASDAQ
Compare
-
Can-Fite BioPharma Ltd.
CANF
·
New York Stock Exchange Arca
Compare
-
BioVie Inc.
BIVI
·
NASDAQ
Compare